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Abstract
Life span extending mutations in growth signaling pathways protect against age-dependent DNA
damage in yeast and decrease insulin resistance and cancer in mice. To test their effect in humans,
we monitored for 22 years Ecuadorian subjects with mutations in the growth hormone receptor
gene leading to severe growth hormone receptor (GHR) and IGF-I deficiencies and combined this
information with surveys to identify the cause and age of death for subjects who died before this
period. The individuals with GHR deficiency (GHRD) exhibited only one non-lethal malignancy
and no cases of diabetes, in contrast to 17% cancer and 5% diabetes prevalence in the controls. A
possible explanation for the very low incidence of cancer may be revealed by in vitro studies:
serum from GHRD subjects reduced DNA breaks but increased apoptosis in human mammary
epithelial cells (HMECs) treated with hydrogen peroxide. We also observed reduced insulin
concentrations (1.4 μU/ml vs. 4.4μU/ml in unaffected relatives) and a very low homoeostasis
model assessment of insulin resistance (HOMA-IR) index (0.34 vs. 0.96 in unaffected relatives) in
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GHRD individuals, indicating increased insulin sensitivity, which could explain the absence of
diabetes in these subjects. Incubation of HMECs with GHRD serum also resulted in reduced
expression of RAS, PKA and TOR, and up-regulation of SOD2, changes that promote cellular
protection and life span extension in model organisms. These results provide evidence for a role of
evolutionarily conserved pathways in promoting aging and diseases in humans and identify a
candidate drug target for healthy life span extension.
INTRODUCTION
Reduced activity of growth hormone (GH) and insulin like growth factor-I (IGF-I) signaling
proteins or of their orthologs in lower organisms, and the activation of stress resistance
transcription factors and antioxidant enzymes, contribute to extended life span and
protection against age-dependent damage or diseases (1-15). Pathways that normally
regulate growth and metabolism also promote aging and genomic instability, a
correspondence that is conserved in simple eukaryotes and mammals (7, 16-18). In yeast,
life span extending mutations in genes such as SCH9, the homolog of mammalian S6K,
protects against age-dependent genomic instability (19-21). Similarly, mutations in the
insulin/IGF-I like signaling (IIS) pathway increase lifespan and reduce abnormal cellular
growth in worms, and mice deficient in GH and IGF-I are not only long-lived but also
exhibit a delayed occurrence of age-dependent mutations and neoplastic disease (5, 6,
22-26). Among the most frequently detected mutations in human cancers are those that
activate the two main signaling proteins downstream of the IGF-I receptor: Ras and Akt, and
those in the IGF-1 receptor itself (27, 28). This is in agreement with a potential role for the
IGF-I signaling pathway in promoting age-dependent mutations that lead to the generation
of oncogenes and for oncogenes in exacerbating the generation of additional mutations and
changes required for cancer progression (29). It has been proposed that the growth-
promoting and anti-apoptotic functions of the IGF-1 pathway underlie its putative role in
cancer development and progression (30). This link is supported by some population studies
but not others which instead indicate only a modest association between high IGF-I
concentrations and increased risk of certain cancers (30, 31).
GH may also promote insulin resistance. For example, age-dependent insulin resistance is
reduced in GH deficient mice (32-35), and GH replacement therapy can exacerbate insulin
resistance in GH-deficient individuals (36, 37), apparently because it causes a switch from
glucose metabolism to lipolysis (38).
Here, we show that the fundamental link between pro-growth pathways, oxidative stress,
age-dependent genomic instability and cellular damage observed in yeast (2, 15, 19-21),
worms and mice (5, 6, 22-26) is conserved in humans by reporting on a 22-year monitoring
of an Ecuadorian cohort with GHR and IGF-I deficiencies and by investigating the effect of
these deficiencies on the cellular response to stress and on markers of cancer and diabetes.
RESULTS
Ecuadorian cohort
Study subjects were 99 individuals with GHRD who have been followed by one of the
authors (J.G-A) at the Institute of Endocrinology, Metabolism and Reproduction (IEMYR)
in Ecuador since 1988 (Fig. 1 A, B). Of these, 9 subjects died during the course of
monitoring. The age distribution of the 90 living GHRD subjects and the control Ecuador
population is shown in Fig. 1 C (39). Using a questionnaire (Table S1), we collected
mortality data for 53 additional GHRD subjects who died prior to 1988 and obtained
information on illnesses and cause of death for 1606 unaffected first to fourth degree
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relatives of the GHRD subjects. The GHRD cohort was identified on the basis of the severe
short stature of the subjects (Fig. 1 A, B) (40-42) and confirmed by genotyping (Fig. 1 D).
The majority of GHRD subjects in this cohort were homozygous for an A to G splice site
mutation at position 180 in exon 6 of the growth hormone receptor (GHR) gene (Fig. 1 D).
This mutation, termed E180, results in a protein that lacks 8 amino acids in its extracellular
domain and is possibly misfolded and degraded (43). Two GHRD subjects were
homozygous for the R43X mutation, which results in a truncated GHR protein as a result of
a premature stop codon (Fig. 1 D) (44) and two GHRD subjects were E180/R43X
heterozygotes (Fig. 1 D).
To confirm IGF deficiency in this cohort, we measured IGF-I and IGF-II concentrations
(Fig. 1 E) in 13 relatives and 16 GHRD subjects ranging in age from 20 to 50 years,
including those whose serum was later used for in vitro studies. Serum IGF-I ranged from
29 to 310 ng/ml (mean 144) among relatives, but was ≤ 20 ng/ml in all GHRD subjects (Fig.
1 E). Serum IGF-II ranged from 341-735 ng/ml (mean 473) among relatives , but was below
164 ng/ml in all GHRD subjects (Fig. 1 E). There was no overlap in the range of IGF-I and
IGF-II serum values between GHRD subjects and relatives (p<0.0001) (Fig. 1 E).
High mortality from common diseases of childhood has been observed in the GHRD cohort
(Fig. 1 F) (45). Because of this, we only considered individuals who survived to at least age
10 for further analysis of diseases in this cohort. Of the 30 deaths among GHRD subjects
(data from both monitoring and surveys) over the age of ten, 9 were due to age-related
diseases (8 cardiac disease, 1 stroke) and 21 were due to non-age-related causes. Compared
to their relatives, GHRD subjects died much more frequently from accidents, alcohol-related
causes and convulsive disorders (Fig. 2 A).
Cancer was not a cause of death in GHRD subjects of any age group; however, it accounted
for 20% of deaths in the relatives (Fig. 2 A, B). Stomach cancer was the predominant cause
of cancer-related mortality in the relatives (Fig. 2 C), which is consistent with the high
incidence of this cancer in Ecuador (46) Among deaths in each age group, the proportion
from cancer was lower in the GHRD subjects than in relatives (based on the exact
hypergeometric distribution as implemented in StatXact 7, CytelSoftware Corporation,
p=0.003). Cancer accounted for 17% of all diseases in the relatives (Fig. 2 D). Of all the
GHRD subjects monitored since 1988, only one was diagnosed with cancer, a papillary
serous epithelial tumor of the ovary in 2008. After treatment, she remains cancer free. We
did not observe any mortality or morbidity due to Type 2 diabetes in the GHRD cohort, but
diabetes was responsible for 5% of the deaths and 6% of all diseases in the relatives (Fig. 2
A, D), in agreement with the 5% prevalence of diabetes in Ecuador (Fig. 2 E) (47). We
estimated the prevalence of diabetes in the GHRD cohort as 0/90 = 0%, with 95% exact
Clopper-Pearson Confidence Interval: 0% - 4%. To test whether the diabetes prevalence in
the GHRD cohort was different from the general population prevalence of 5%, we
performed an exact test of the null hypothesis that p=0.05, based on the Binomial
distribution, with the type I error rate, α=0.05. The P-value was 0.02, indicating that the
prevalence in the GHRD cohort is less than 5%. This is a particularly striking result
considering the elevated prevalence of obesity among these GHRD individuals (21% in
GHRD subjects vs. 13.4% in Ecuador) (Fig. 2 E) (46). To investigate the mechanisms that
could be responsible for the observed lack of diabetes in the GHRD cohort, we measured
fasting glucose and insulin concentrations in 13 relatives and 16 GHRD subjects consisting
of both male and female subjects between the ages of 20 and 50. We observed no significant
difference in fasting glucose concentrations between them (Fig. 2 F). However, the average
insulin concentration in the GHRD group was approximately a third of that in the relatives
(Fig. 2 G, p<0.05), and the HOMA-IR index (48) indicated that GHRD subjects (HOMA-IR
=0.34) were much more insulin sensitive than relatives (HOMA-IR=0.96) (Fig. 2H, p<0.05).
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These results are consistent with the finding that GHRD mice and other GH deficient mouse
models have low serum insulin concentrations and are insulin sensitive (32-35).
Although GHRD subjects may have elevated cardiac disease mortality compared to their
relatives (Fig. 2 A), the relative mortality from vascular diseases (combining cardiac disease
and stroke) appears to be similar (33% of deaths in relatives vs. 30% of deaths in GHRD
subjects) (Fig. 2 A). In agreement with studies of a human population with isolated growth
hormone deficiency (49), our data suggest that GHRD does not increase overall vascular
disease mortality (Fig. 2 A).
Reduced IGF-1 signaling protects against DNA damage but favors apoptosis of damaged
cells
Our studies in S. cerevisiae indicate that homologs of mammalian growth signaling pathway
genes, including TOR, S6K, RAS, adenylate cyclase and PKA promote an age-dependent
increase in DNA mutations by elevating superoxide production and promoting DNA damage
independently of cell growth (20, 21). Notably, the mutation spectrum in p53 from human
cancers is similar to that in aging yeast (19, 20, 29). These results raise the possibility that
GH and IGF-I signaling may promote mutations and cancer not only by preventing
apoptosis of damaged cells but also by increasing DNA damage in both dividing and non-
dividing cells. To test this hypothesis, we incubated confluent human mammary epithelial
cells (HMECs) in medium supplemented with 15% serum from either relatives or GHRD
subjects (50, 51) for 6 hours and then treated them with H2O2 for 1 or 24 hours, followed by
comet analysis to detect DNA strand breaks. The cells were cultured in medium devoid of
serum. In order to prevent interference from growth factors or insulin, the medium did not
contain any growth supplements during the 6-hour incubation period. Because cells were
incubated to greater than 90% confluence, cell growth during the pre-incubation and H2O2
treatment periods was minimal. Comet analysis indicated that cells incubated in serum from
GHRD subjects had fewer DNA breaks after treatment with 700μM H2O2 for 1 hour (Fig. 3
A, B) or 24 hours (Fig. 3 A, C) compared to cells incubated in serum from relatives. This
suggests that serum from GHRD subjects can protect against oxidative DNA damage
independently of cell division. We also incubated confluent HMECs in medium
supplemented either with serum from relatives, GHRD serum, or GHRD serum
supplemented with 200ng/ml IGF-I for 6 hours (normal levels of IGF-I in Ecuadorian adults
range between 96-270 ng/ml) (40). Treatment with 700μM H2O2 resulted in higher
cytotoxicity in cells incubated in GHRD serum than in control serum (Fig. 3 D). This effect
was completely reversed by the addition of 200ng/ml IGF-I to GHRD serum (Fig. 3 D).
HMECs also displayed higher caspase activity in response to H2O2 when incubated in
GHRD serum rather than serum from relatives (Fig. 3 E), in agreement with the proposed
role of IGF-I signaling in increasing cancer incidence by preventing apoptosis (29). We also
observed increased cytotoxicity in mouse embryonic fibroblast (MEF) cells in response to
H2O2 following incubation in GHRD serum (Fig. 3 F)
To test whether IGF-I signaling was responsible for the sensitization of cells to oxidative
damage, we analyzed DNA damage in MEF cells lacking the IGF-I receptor (R-cells) or
overexpressing the human IGF-I receptor (R+ cells) (52). R+ cells had higher basal DNA
than did R-cells (Fig. 3 G). Western blot analysis confirmed the anticipated increase in
phosphorylation of Akt (Thr 308) and FoxO1 (Ser 256) in R+ cells compared to R-cells,
indicating that Akt was activated while FoxO1 was inactivated in the R+ cells (Fig. 3 H)
(53-55). The very low level of total FoxO1 protein in R+ cells may be due to the Akt-
mediated phosphorylation of FoxO, which results in its ubiquitination and proteasomal
degradation (Fig. 3 H) (56). Reduced FoxO activity in R+ cells when compared to R-cells
that were transfected with a FoxO luciferase reporter plasmid confirmed that FoxO was
inactivated by high IGF-I signaling in these cells (Fig. 3 I). As FoxO transcription factors
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are known to protect against oxidative stress as well as promote apoptosis (54, 57, 58), we
hypothesize that increased FoxO activity could account, in part, for the protective effects
observed in HMECs incubated in GHRD serum. In support of this, microarray analysis of
HMECs incubated in either control or GHRD serum showed that out of 44 genes that were
significantly up-regulated in the GHRD serum-treated group, 4 genes, including SOD2,
were FoxO targets (Fig. 3 J).
Protective effects of reduced pro-growth signaling in yeast and mammals
A complete list of genes with significant differential expression in HMECs incubated in
either control or GHRD serum is shown in Table S2. Ingenuity Pathways Analysis (IPA) of
global gene expression patterns revealed significant differences in pathways involved in cell
cycle regulation, gene expression, cell movement and cell death, among others (Fig. S1).
IPA also indicated that genes regulating apoptosis were up-regulated (Fig. S2) whereas Ras,
PKA and Tor signaling were down-regulated in cells incubated in GHRD serum (Fig. S3).
RT-PCR analysis confirmed a 30% higher mRNA level of mitochondrial MnSOD (SOD2)
in cells incubated in GHRD serum, and also a 70%, 50% and 20% reduction in N-Ras, PKA
and TOR expression, respectively (Fig. 4 A). Ras, PKA and TOR/S6K are central regulators
of pro-aging and disease promoting pathways (59) and SOD2 is a key mediator of cellular
protection against oxidative stress in organisms ranging from the unicellular yeast to
mammals (2, 19, 20, 60-63).
To further test the role of these genes in age and oxidative stress-dependent DNA damage,
we generated a yeast triple mutant strain lacking RAS2, TOR1 and SCH9. Our previous
studies have shown that yeast sch9Δ mutants exhibit lower age-dependent genomic
alterations than wild-type cells in part due to reduced error-prone Polζ-dependent DNA
repair (20). We observed a 4-fold life span extension in triple mutants compared to wild-
type cells (Fig. 4 B). We analyzed age-dependent DNA genomic instability in the
ras2Δtor1Δsch9Δ and wild type cells by measuring the frequency of mutations of the
CAN1 gene. Mutations that inactivate the arginine permease encoded by CAN1 can be
easily measured since they allow cells to grow in medium containing the normally toxic
arginine analog canavanine (64) The frequency of age-dependent mutations in the CAN1
gene, which are mostly point mutations including a high frequency of G to T (transversion)
and C to T (transition) base substitutions (19), were much higher in wild type cells
compared to the ras2Δtor1Δsch9Δ mutants (Fig. 4 C). Whereas wild-type cells were
susceptible to H2O2 treatment, the ras2Δ tor1Δ sch9Δ mutants were almost unaffected at
the concentrations tested (Fig. 4 D) and were highly protected against oxidative stress-
dependent mutations (Fig. 4 E).
DISCUSSION
Our finding that human GHRD subjects are protected against age-related pathologies is
consistent with the elevated cellular protection in both yeast and human cells with reduced
expression of specific pro-growth genes and with the effect of serum from GHRD subjects
in lowering their expression (Fig. 4 F). Our results also show similarities with GHRD mice,
which display lower incidence (49%) and delayed occurrence of fatal neoplasms and
increased insulin sensitivity (24, 25, 32). Furthermore, the reduced cancer incidence in
GHRD mice is associated with a lower mutation frequency in various tissues (26).
The lack of lifespan extension in GHRD subjects may be explained in large part by the
major proportion of deaths (70%) caused by convulsive disorders, alcohol toxicity,
accidents, liver cirrhosis and other non-age-related causes. The lack of cancer mortality but
normal life span in GHRD subjects, is in agreement with a preliminary study that reported
the absence of cancer in a group of 222 patients with congenital IGF-I deficiencies (65) and
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with the normal lifespan that was observed in 65 GH deficient subjects (66). In contrast to
our study of GHRD subjects with specific mutations and their age-matched relatives, Shevah
and Laron compared young subjects with IGF-I deficiencies due to many causes, with much
older controls, which made it difficult to determine whether cancer incidence was reduced
(65). However, taken together these two studies provide strong evidence for reduced cancer
incidence in GHR and IGF-I deficient subjects, and indicate that IGF-I could serve as a
marker for age-dependent cancer, at least in specific populations. Our results may also
provide a partial explanation for the overrepresentation of partial loss-of-function mutations
in the IGF-1 receptor gene among Ashkenazi Jewish centenarians (67).
The role of IGF-I in cancer may involve the well-established pro-growth and anti-apoptotic
functions of this growth factor(30, 68, 69) as well as an effect on increasing oxidative
damage and DNA damage independently of growth as suggested by our studies in yeast
(19-21, 29) and mammals (70, 71). In both yeast and mammals, reduction of TOR/S6K,
RAS and AC/PKA signaling renders cells and the organism resistant to age- and oxidative
stress-dependent mutagenesis (2, 15, 19-21, 70, 72, 73). This effect appears to depend, in
part, on increased activity of stress resistance transcription factors and SOD2 (20, 57, 63). In
fact, mice lacking Cu/Zn SOD or MnSOD are susceptible to increased DNA damage and
cancer (62). The positive effects of serum from GHRD subjects on cellular changes that
promote longevity in model organisms, such as reduced levels of RAS, PKA, and TOR and
increased expression of SOD2 and other FoxO-regulated genes, suggests that the anti-aging
and anti-DNA damage mechanisms promoted by reduced growth signaling are conserved
from yeast to humans (Fig. 4F) (7, 16, 74).
The lack of type 2 diabetes in the GHRD cohort, is particularly interesting considering that
obesity is one of the clinical phenotype of GHRD. The enhanced insulin sensitivity of
GHRD subjects, as indicated by reduced insulin concentrations and a lower HOMA-IR
index, could explain the absence of diabetes in this cohort. Although, increased insulin
sensitivity has been associated with a longer lifespan, some long-lived mice including the fat
insulin receptor knockout (FIRKO) mice, exhibit impaired insulin signaling. In this case
however, loss of insulin signaling is restricted to adipose tissue and is not associated with
diabetes or glucose intolerance (75). Similarly, male IGF-I receptor heterozygous (IGF 1R
+/-) mice show a 16% increase in lifespan although they exhibit impaired glucose tolerance
(6). The anti-aging benefits of reduced GHR and IGF-I signaling without the detrimental
effects of insulin resistance in GHRD mice may explain, in part, why they display reduced
disease incidence and a much longer lifespan compared to IGF 1R +/- mice.
Our results provide a foundation for further investigation into the role of drugs blocking the
GHR and downstream conserved pro-aging pathways to prevent or reduce the incidence of
cancer, diabetes and other age-related diseases including inflammatory disorders, stroke, and
neurodegenerative diseases.
MATERIALS AND METHODS
Subject Recruitment
GHRD subjects and their relatives were recruited for the study under protocols approved by
the Institute for Endocrinology, Metabolism and Reproduction (IEMYR) in Ecuador. All
participants signed informed consent forms prior to their participation in the study. Data on
deceased GHRD subjects was collected from family members using a detailed questionnaire
(Table S1). At least two relatives were required to be present at the time of the interview.
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Genotyping
Saliva samples were collected using the Oragene OG-250 DNA collection kit (DNA
Genotek Inc., Ontario, Canada) and processed according to the manufacturers protocol.
Genotyping of the E180 mutation was performed using the following primers - 5′-
CATTGCCCTCAACTGGACTT-3′ Forward 5′-
CATTTTCCATTTAGTTTCATTTACT-3′ Reverse (WT) 5′-
CATTTTCCATTTAGTTTCATTTAC-3′ Reverse (mutant)
Serum Analysis
Serum IGF-I was measured using an in-house ELISA immunoassay based on paired specific
antibodies (R&D systems) and validated against the commercial kit from Diagnostic
Systems Laboratories. The assay was performed after acid/ethanol extraction of the samples
and has a sensitivity of 0.2ng/ml. IGF-II was measured using paired anti-IGF-II specific
antibodies (R&D systems). The sensitivity of the assay is 0.2 ng/ml. Fasting glucose levels
were measured with a glucose analyzer from YSI Life Sciences and fasting insulin levels
were measured with a human insulin ELISA kit from Millipore. Insulin resistance was
assessed using the homeostatic model assessment-insulin resistance (HOMA-IR) index from
fasting glucose and fasting insulin values (48).
Cell culture
HMECs were purchased from ScienCell Research Laboratories. Cells were cultured in
epithelial cell medium (ScienCell) at 37°C and 5% CO2 on poly-L-lysine (Sigma) coated
culture dishes. The epithelial cell medium consisted of basal medium and a proprietary
growth supplement supplied by the manufacturer and no serum. Primary mouse embryonic
fibroblasts (MEFs) were purchased from ATCC and cultured in DMEM/ F12 (Invitrogen),
supplemented with 15% FBS at 37°C and 5% CO2. R+ and R-cells were obtained from Dr.
R. Baserga and cultured in DMEM/F12 supplemented with 10% FBS at 37°C and 5% CO2.
Cells were seeded at a density of 4×104 per well for comet and apoptosis assays, 8×104 per
well for LDH assays or 2×105 per well for microarray analysis and western blots in 24, 96
and 6 well plates respectively. HMECs and MEFs were incubated in basal medium
supplemented with 15% serum from relatives or GHRDs for 6 hours followed by treatment
with H2O2 for 1 hour (comet and apoptosis assays) or 24 hours (comet and LDH assays).
Incubation of HMECs in human serum was done in basal medium without the growth
supplement while that for MEFs cells was done in DMEM/F12 without FBS. For microarray
analysis, HMECs were incubated in serum from relatives or GHRDs as above for 6 hours
and immediately processed for RNA extraction with TRI reagent from Ambion.
Comet Assay
Comet assay was performed according to the method described by Olive et al (76) using the
comet assay kit from Trevigen. DNA damage was quantified per cell with the Comet Score
software. 100-200 cells were analyzed per sample.
LDH assay
LDH activity was assayed in culture medium with the CytoTox 96 Non-Radioactive
Cytotoxicity Assay from Promega according to the manufacturer’s protocol.
Apoptosis assay
Activated caspases were quantified with a fluorescence plate reader with the Fluorescein
CaspaTag Pan-Caspase Assay Kit (Chemicon) according to the manufacturer’s protocol.
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FoxO activity
50,000 cells/well were transfected with 0.2μg of FoxO luciferase reporter plasmid with the
consensus FoxO binding sequence driving firefly luciferase gene expression in 24 well
plates. As an internal control cells were co-transfected with 0.02μg of plasmid DNA
encoding Renilla luciferase under control of the CMV promoter. 24 hours after transfection,
FoxO promoter activity was assayed using the Dual-Luciferase Reporter Assay System from
Promega according to the manufacturer’s protocol. Western blot analysis: Cells were lysed
in RIPA buffer and total protein was assayed with BCA from Thermo scientific. 15 μg of
total protein was loaded on denaturing 10% SDS-PAGE gels. Primary antibodies against
phosphorylated and total Akt (Thr 308) as well as phosphorylated and total FoxO1 (Ser 256)
were obtained from Cell Signaling Technologies. Anti β-tubulin antibody was obtained from
Santa Cruz Biotechnology Inc. Secondary rabbit antibody was obtained from Jackson
Immunoresearch Laboratories, Inc. Microarray analysis: RNA was extracted using TRI
Reagent (Ambion) and hybridized to BD-103-0603 chips from Illumina Beadchips (San
Diego, CA). Raw data were subjected to Z normalization and are available at the gene
expression omnibus (GEO) repository, accession number GSE21980. Gene set enrichment
was tested with the PAGE method as described (77).
Figures S6, S7 and S8 were selected based on the names and descriptions provided by
Ingenuity Pathways Analysis (Ingenuity Systems; Redwood City, CA) and/or Ariadne
Pathway Studio 7 (Ariadne Genomics).
Yeast
Wild type DBY746 (MATα leu2-3 112 his3Δ ,trp1-289 ura3-52 GAL+) and its derivative
ras2::LEU2tor1::HIS3sch9::URA3, originated by one-step gene replacement, were grown in
SDC containing 2% glucose(2). Chronological life span in SDC medium was monitored by
measuring colony forming-units (CFUs), on YPD plates, every other day. The number of
CFUs on day one was considered to be the initial survival (100%) and was used to
determine the age-dependent mortality (78). Spontaneous mutation frequency was evaluated
by measuring the mutation frequency of the CAN1 (YEL063C) gene. Cells were plated onto
selective SDC minus Arginine plates in the presence of L-canavanine sulfate (60mg/L).
Mutation frequency was expressed as the ratio of Canr colonies over total viable cells (64).
Resistance to oxidative stress was also evaluated in yeast cultures chronically treated with 1
mM H2O2 on days 1 and 3.
Statistical analysis
Students t-test, two tailed, was used to analyze insulin, HOMA-IR data, and cellular data
from mammalian (comet, LDH, caspase assays, RT-PCR, and FoxO activity) and yeast
experiments (survival and mutation frequency) using graph pad prismV.
SUPPLEMENTARY MATERIAL Fig. S1 Functional clustering of genes with significant
differential expression in HMECs incubated in either serum from relatives or GHRD serum.
Fig. S2 Ingenuity pathways analysis indicating an upregulation of apoptosis in HMECs
incubated in GHRD serum. (Red=Up-regulation, Blue= Down-regulation)
Fig. S3 Ingenuity pathways analysis indicating downregulation of Ras, PKA and RPS6K in
HMECs incubated in GHRD serum. (Red=Up-regulation, Blue= Down-regulation)
Table S1 Questionnaire
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Table S2 List of genes with significant differential expression in HMECs incubated in either
serum from relatives or GHRD serum.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Fig. 1.
Ecuadorian cohort. (A, B) Several members of the GHRD cohort with Dr. J-G.A. in (A)
1988 and (B)2009 (C) Age distribution for 90 living GHRD subjects and the Ecuadorian
(Control) population (D) Genotypes of the GHRD cohort. All GHRD subjects were
identified based on short stature and very low IGF-I levels. Undetermined refers to subjects
whose genotypes have not been confirmed (E) Serum IGF-I and IGF-II levels in 13
unaffected relatives and 16 GHRD subjects ***p<0.0001. (F) Survival of the GHRD cohort.
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Fig. 2.
Diseases and mortality in the Ecuadorian cohort (A) Causes of death in unaffected relatives
and GHRD subjects (B) Percentage of cancers per age group in unaffected relatives and
GHRD subjects. (C) Percent distribution of cancer-deaths in the unaffected relatives (D)
Percentage of cancer and type II diabetes in unaffected relatives and GHRD subjects. Data
are shown as a percentage of all diagnosed/reported diseases. ^ = 1 case of cancer and # = no
case of diabetes has been recorded. (E) Percent prevalence of obesity and type II diabetes in
Ecuador (control) and GHRD subjects. # = no case of diabetes has been recorded in the
GHRDs. Obesity prevalence in Ecuador is based on WHO reports for 2010 (79) while that
for GHRD subjects was calculated based on BMI > 30 kg/m2. Prevalence of type II diabetes
in Ecuador was obtained from the study by Shaw S.E. et al (47). (F) Fasting glucose (G)
fasting insulin and (H) insulin resistance represented by HOMA-IR in relatives and GHRD
subjects. Data represent mean ± SEM for 13 control and 16 GHRD samples. * p<0.05.
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Fig. 3.
Reduced IGF-1 signaling protects against DNA damage and favors apoptosis of damaged
cells. (A,B,C) Comet assay to analyze DNA damage in HMECs incubated in serum from
relatives/GHRDs and treated with H2O2 for 1 hour or 24 hours (A) Representative
micrographs of cells treated with 700 μM H2O2 (B, C) Tail olive moment in cells treated
with H2O2 for (B) 1 hour or (C) 24 hours. Data represent mean ± SEM. At least 6 serum
samples were tested per group and 100-200 cells were analyzed per sample. (D) LDH
activity in HMECs incubated in serum from relatives/GHRDs and treated with H2O2 for 24
hours. Data represent mean ± SEM. 6 serum samples were tested per group in triplicates. (E)
Activation of caspases in HMECs incubated in serum from relatives/GHRDs and treated
with H2O2. Data are calculated as percentage of untreated control and represent mean ±
SEM. 6 serum samples were tested per group. (F) LDH activity in MEFs incubated in serum
from relatives/GHRDs and treated with H2O2 for 24 hours. Data represent mean ± SEM. 6
serum samples were tested per group in triplicates. (G) Tail olive moment to measure basal
DNA damage in R+ (IGF-IR overexpression) or R-(IGF-IR deficient) mouse embryonic
fibroblasts (MEFs). Data represent mean ± SEM. 100-200 cells were analyzed per sample.
(H) Representative western blot showing phosphorylation status of Akt (Ser 473) and
FoxO1 (Ser 256) in R+ and R-cells. (I) FoxO activity in R+ and R-cells transfected with a
luciferase reporter plasmid (I) List of FoxO target genes significantly upregulated in
HMECs incubated in GHRD serum versus serum from relatives, *p<0.05, **p<0.01,
***p<0.0001.
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Fig. 4.
Protective effects of reduced pro-growth signaling in yeast and mammals (A) RT-PCR
indicating upregulation of SOD2 and downregulation of N-Ras, PKA and TOR in HMECs
incubated in GHRD serum compared to cells incubated in serum from relatives (B)
Chronological survival of wild-type (WT) yeast cells and ras2Δsch9Δtor1Δ mutants cells
(C) Mutation frequency over time in the CAN1 gene (measured as Canr mutants/106 cells).
(D) Chronological survival of wild-type yeast cells and ras2Δsch9Δtor1Δ triple mutants
treated with H2O2 (E) Mutation frequency over time in the CAN1 gene (measured as Canr
mutants/106 cells) in H2O2 –treated yeast cells. Data represent mean ± SEM, n= 5. *p<0.05,
**p<0.01 compared to untreated WT cells and ^ p<0.05, ^^p< 0.01 compared to untreated
ras2Δ, sch9Δ, and tor1Δ triple mutants. (F) Conserved growth factor signaling pathways in
mammals and yeast.
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